Marvelous Microcaps

Back to All

Biomerica, Inc.: A health diagnostics company preparing to move up the value chain

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have a high conviction in their success; companies that are out of the mainstream of small cap investing. To highlight our process, we are pleased to present the newest installment in our ongoing series “Marvelous Microcaps – Big Ideas on Small Companies.”  This series profiles companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

Biomerica, Inc., (BMRA) is a biomedical technology company that designs, develops, and manufactures laboratory and at home testing applications for various medical conditions and diseases. They are a commercial stage company, with products in the marketplace that test for conditions such as colorectal, breast, and prostate cancers as well as diabetes, kidney diseases and gastrointestinal afflictions. They are also in the late developmental stages of an exciting new laboratory application called InFoods. InFoods is a patented blood test for patients with irritable bowel syndrome, or IBS, which detects elevated antibody levels found in the human blood system and can match them to foods that are specific or highly correlated to disease states reported by patients. Utilizing an extensive database of control subjects the parameters and statistical sensitivities of the test can be customized to fit the needs of the patient and deliver results that report which foods are aggravating their condition with a high degree of confidence. There are an estimated 25-40 million Americans with IBS and related issues, most of whom are undiagnosed. The most common reported factor that contributes to the severity of IBS in patients is pain. Since IBS is chronic in most patients, the standard of care currently is guess work on dietary changes and pain medication to alleviate symptoms. InFoods aims to address both deficiencies head on by identifying which foods pose the most harm to patients allowing doctors and nutritionists the opportunity to customize a diet plan and improve patient outcomes, the quality of their day-to-day lives and address the underlying disease rather than use pain medications to manage its symptoms.

WHY WE OWN: THE PERRITT ADVANTAGE

We purchased Biomerica several years ago, shortly prior to the pandemic after speaking with the CEO, Zack Irani. At that time, the company had just received encouraging results on the first generation of the technology that would become InFoods. While investments in early-stage healthcare diagnostic and drug companies are normally avoided due to the risks in the development pipeline, Biomerica had already successfully gone to market with their cancer diagnostics products and at the time had just announced a distribution agreement with Medline, a large healthcare supply company. We found that this revenue stream, though small, was growing steadily and believed it removed some of the funding risks so decided to take a small position. Since that time Biomerica has conducted several rounds of Research &Development and investment in their product. They recently announced the final results for their end point trial for InFoods that showed statistically significant improvement for patients that used their laboratory test in areas including pain, bloating and overall quality of life. The next step for the company is to submit a proposal to the FDA for a pivotal trial, which if successful would be followed by full FDA approval for their test to be licensed for use in patients in commercial labs. If everything goes according to schedule this trial would commence during the end of 2023.

However, in the interim the company has the capability to offer the test through specialized clinical laboratories, so they have announced that they are commercializing InFoods during the final months of 2022 within those labs that qualify. Highlighted institutions in the company’s press release include the Mayo Clinic and Beth Israel Deaconess Medical Center. While it is too early stage to gauge the potential revenue impacts from the launch, we are excited to see the efforts of the company and our investment thesis validated in the marketplace and believe these efforts will provide the company with some additional cash flow as they prepare for the final push for full commercialization of InFoods.

We remain excited shareholders and are pleased to be able to share this emerging healthcare technology company with you. We consider Biomerica to be among our more speculative holdings given the regulatory risks associated with the FDA approval process. As they move further along in that process these risks will continue to diminish but at this time, they represent the biggest obstacle to the company’s long-term prospects. While the successful end point trial and limited commercialization is an encouraging development, we also emphasize that Biomerica is an early-stage company that we chose to highlight here to illustrate the variety of investments we hold in our funds and that we would only hold it as part of a well-diversified portfolio. Currently, we only own it in our Ultra Microcap Fund due to the speculative nature of the investment.

2022 Perritt Funds Tax Distribution Update

We anticipate the Perritt MicroCap Opportunities Fund and the Perritt Ultra MicroCap Fund will pay a capital gains distribution on 11/23/22 to shareholders.  Based on our estimates:

• The long-term capital gains distribution in the Perritt MicroCap Opportunities Fund (PRCGX) was $0.75629 per share.  The Perritt Ultra MicroCap Fund (PREOX) long-term capital gains distribution was $0.18381 per share.
• Any income or short-term gains in our Funds will be paid on 12/22/22 to shareholders of record on 12/21/22.  However, neither fund is expected to have a short-term capital gain or income distribution.

Distribution figures and distribution dates are estimates only and are subject to change. Actual distributions may be substantially different (higher or lower) or may not be distributed at all.

Actual distributions on a dollar per share basis will be available on or after 11/23/2022.

Please visit our website at www.perrittcap.com/index.php or call 1-800-331-8936 for more information.  Thank you for your investment and trust in the Perritt Team.

Click here for research and insights regarding small company investing.

Click here for a prospectus.

The Shyft Group, Inc.: Deliveries R Us

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have a high conviction in their success; companies that are out of the mainstream of small cap investing. To highlight our process, we are pleased to present the newest installment in our ongoing series “Marvelous Microcaps – Big Ideas on Small Companies.”  This series profiles companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

 The Shyft Group (SHYF) offers an unparalleled roster of commercial, retail, service specialty vehicle, and upfit brands. They uniquely combine in-depth industry knowledge, engineering and manufacturing expertise, and purposeful innovation to deliver job-enhancing efficiency-driving, ever-reliable products, and services. Their newest product is the exciting Blue Arc to support the Electric Vehicle (EV) transition. “Our industry has a responsibility to create a more environmentally sustainable future.” They are currently the only supplier in the Class 3 to Class 5 EV manufacturing. In addition, their Power Cube offers the ability to charge a fleet without significant investment by their customers. 

WHY WE OWN: THE PERRITT ADVANTAGE

 SHYF exemplifies what we look for in a microcap stock. Their sales have grown from $550 million in 2015 to $992m in 2021, adjusted EBITDA grew from 2.0% to 10.9% and the share price from $3.11 to $21.58 and the current price is around $22. They have both grown organically and deployed $100m toward acquisitions. Their goals are to have revenue of $1.75 billion and adjusted EBITDA of 15% by the year 2025. There is also a focus on ESG with energy efficient processes, investment in the electric vehicle portfolio, waste/water management, among others. The new EV initiative should start a substantial payback in 2025. They have secured ~40% of volume with a recent pre-order, expect $500-600m in revenue from this division alone in 2025 and have ~12% payback on their initial investment. In short, they have an excellent management track record of transforming a company, best-in-class commercial grade product, and a rock-solid balance sheet. 

Bear Market Internals

Michael Corbett
CEO, CIO, Portfolio Manager

While each of the domestic indexes have clearly entered bear market territory, the average stock has experienced a far greater decline. Whether it is an individual stock or a broad index, bear markets are defined as declines of more than 20% from past their highs.  As you can see in the table below, the bear market has reached each index with ranges of a 21.9% decline for the Dow Jones Industrial Average to the Russell Microcap Index decline of 34.6%.  Each of these declines are as of September 30, 2022.

The average stock has experienced declines of 30.2% for Dow stocks to a whopping 52.3% for the average stock within the Russell Microcap index.  The reason the declines are worse for the average stock versus the index is related to how stocks are weighted in each of these indexes.  The Dow Industrial Average is weighted by a stock’s price.  The other indexes are weighted by their market capitalization.  For example, a stock like United Health Group (UNH) comprises more than 10% of the Dow due to its price more than $500 per share versus the average stock in the index is priced at only about $145.  For the S&P 500 Index, the most heavily weighted stock is Apple (AAPL) at approximately 8% of the index due to its market capitalization of more than $2.3 trillion.  Each of these stocks I mentioned have declined less than the average stock as well as less than their respective index.

The table below shows the percentage of stocks that declined in ranges.  As you can see, smaller companies have experienced greater declines in this bear market.  While this is not a major surprise, we argue these declines give us confidence we are closer the end of the bear market than the beginning or the middle.

Here are a few other data points based on past bear markets.  Since 1940, the average bear market during a recession lasts 13 months and declines 34%.  The average bear market with no recession lasts 6 months and falls 24%.  The current bear is now in its 10^th month with a 25% decline.  There have been eight previous times the S&P 500 has fallen 25% or more.  The average returns following these declines have been 22% after one year, 37% after three, 83% after five, and 214% after ten.  The Russell 2000 Index of small companies peaked in November of 2021 and is down 32.5% from its previous high.  The Russell 2000 has fallen 30% or more in six previous periods, with the average 1-year, 3-year, 5-year and 10-year rebounds being 33%, 49%, 102%, and 228%.

What’s Next?

Remember when Fed Chairman Powell promised to kill inflation a month ago? Inflation is as prominent as ever. We knew prices were going up at the grocery store and it costs more to fill a tank of gas, but now wages are increasing, rents are skyrocketing, and of course mortgage rates are up. The recent .75-point increase is the Fed’s third such hike, boosting borrowing costs at the fastest pace in decades.

What should we expect next?

• We believe the Fed will keep raising rates until it restrains the economy and consumer spending decreases. The thought is that we will likely see rates at 4.4% to 4.6% by the end of the year. Fed Chairman Powell is a big believer that the mistake policymakers repeatedly made in the 1970s was allowing inflation to become more firmly entrenched.
• Higher rates will affect everything you do – credit card rates are the highest since 1996, mortgage rates the highest since 2008 and auto loans the highest since 2012. Consumers with credit card debt will spend an estimated additional $5.3 billion on interest.
• On the plus side, savings rates are up. Top-yielding online savings account rates are as high as 2.5%. However, they may not increase as much or as fast as you would expect.

• The stock market has been declining in anticipation of this move by the Fed. During the five most recent rate hike cycles, the three leading stock market indexes only declined during one rate hike cycle. The period of 2008-2019 was an exceptional period due to the Housing Bubble.

Bowman Consulting Group: An emerging opportunity in the engineering and construction industry

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have a high conviction in their success; companies that are out of the mainstream of small cap investing. To highlight our process, we are pleased to present the newest installment in our ongoing series “Marvelous Microcaps – Big Ideas on Small Companies.”  This series profiles companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

Bowman Consulting Group (BWMN) provides engineering and planning services for construction, transportation, energy, and mining industries. They provide a wide range of services including project planning and management, environmental consulting, design services, and engineering consulting among others. They do not engage in any of the actual construction on a project. Instead, Bowman’s contribution comes in the form of what is called human capital, or in other words their employees and their knowledge base. Bowman has been public since the spring of 2021 with the stated strategy of pursuing a roll-up strategy to grow their national footprint and become a top tier operator in their industry. They operate in a highly fragmented space and management estimates there are well over a thousand private competitors from which to select acquisition candidates. Projects they have been a part of include highway projects for the State of Illinois, infrastructure projects at copper mining sites for Freeport McMoRan, data centers, distribution centers, park and municipal construction, and retail construction projects for national chains, such as Walgreens, 7-Eleven, and Starbucks.

WHY WE OWN: THE PERRITT ADVANTAGE

Perritt purchased Bowman during its IPO based on the strong outlook for the space and our belief that the consulting space within the engineering and construction industry remains ripe with opportunities for consolidation and rapid growth. While roll-up strategies can be risky, we believe that it’s a viable strategy in specific industries where internal capital needs are low, the businesses generate operating profits, and there is a component of the business that requires a physical presence. In the case of Bowman, they operate in a space that requires very little capital expenditures due to low equipment needs; they do not take on project risk as a general contractor thus minimizing their downside risk on specific contracts that could adversely impact operating profitability; and they have demonstrated the ability to grow revenues organically in the double digits while also pursuing their roll-up strategy, so revenue growth is not dependent on acquisitions alone. We previously had remarkable success with an investment in a similar company named NV5 Global (NVEE), which IPO’d in 2013 with revenues of $60.58 million, a market capitalization of $25.26 million at a share price of $6.00. Today, NVEE has revenues of $767 million, a market cap of $2.1 billion, and a share price of $137.17 per share. While we do not know if Bowman will be able to achieve similar success, management has noted NVEE as one of the models for their strategy and we believe it demonstrates the viability of a roll-up strategy in the engineering and construction consulting industry.

The results so far have been encouraging. Since their IPO in the spring of 2021, Bowman has completed twelve acquisitions and grown revenues organically in the double digits. In their last quarterly report, they reported revenues of $62.4 million which represented a growth of almost 71% from the previous quarter in June of 2021 when they were first public. Organic growth has accounted for half of their revenue growth this year, with the other half coming from their twelve acquired businesses. They have generated cash from operations in each quarter since they have been public when the expenses of the IPO process led to modest cash burn of less than $1 million. In terms of headcount, they have grown their staff internally by 10% while also acquiring over six hundred employees of which 92% remain with the company post-merger. In a human-capital driven business, staff retention is paramount, and we believe these numbers reflect management’s success in shepherding their most valuable resources.

We consider Bowman Consulting to be a high conviction name and hold the security in both Perritt Funds. We were able to participate in the IPO by utilizing our external network of research brokerage houses and have continued to add to the position when we have felt conditions were favorable. While it is still early in the process and there are risks involved that could derail their strategy, we believe that the risk/reward with BWMN is attractive and that they are poised to continue growing both organically and through acquisitions for the near future.

Hudson Global, Inc.: provides talent solutions for mid-to-large cap multinational companies and government agencies

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have a high conviction in their success; companies that are out of the mainstream of small cap investing. To highlight our process, we are pleased to present the newest installment in our new series “Marvelous Microcaps – Big Ideas on Small Companies.”  This series profiles companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

Hudson Global, Inc. (HSON) provides customized recruitment process outsourcing (RPO) and total talent solutions to companies worldwide. The company operates in Asia Pacific (70% of 2021 revenues), the Americas (17%), and Europe (13%). RPO is a business model where a company outsources the management of the recruitment function (in whole or in part) to a third-party expert to drive cost, quality, efficiency, service, and scalability benefits.

HSON developed Project RPO to respond to their clients quickly with the ability to fill job roles in less than 30 days. Timely and cost-effective, the average recruitment outsourcing project may be implemented in as little as a few weeks and typically lasts between three to twelve months.

WHY WE OWN: THE PERRITT ADVANTAGE

HSON report their first quarter 2022 earnings per share of $0.97 which exceeded the $0.30 estimate. They earned $1.07 in 2021 and are anticipated to earn $3.24 in 2022 while trading at 11.1x earnings. HSON has marked a strong return after the pandemic by growing revenue 50.6% annually. They have used free cash flow for share repurchases and acquisitions. The October 2020 purchase of Coit Group and November 2021 acquisition of Karani, LLC represent adding complementary service offerings and expanding globally.

Hudson’s key strong point is its exclusive focus on the RPO market over the last couple of years. This market is expected to grow by 10-15% CAGR (Compound Annual Growth Rate) over the next couple of years and they are the only independent company operating in the sector, with others being divisions of larger companies.

We believe the share price does not fully reflect the improving fundamentals, specifically free cash flow generation, long-term EPS growth forecast of 20% and a healthy balance sheet.

Data here is obtained from what are considered reliable sources; however, its accuracy, completeness, or reliability cannot be guaranteed.

Fund holdings and sector allocations are subject to change at any time and should not be considered a recommendation to buy or sell any security. Please click PRCGX and PREOX for a list of the top ten holdings.

 

Perritt.  Marvelous Microcaps – Big Ideas on Small Companies.

 

Bear Market Becomes Official

Michael Corbett
CEO, CIO, Portfolio Manager

The stock market “officially” became a bear market this week, defined as a 20% decline in the S&P 500 Index.  Our regular readers know that we have already been in a bear market for some time.  High flying tech stocks and the Russell 2000 Index of small company stocks both peaked February 2021, sixteen months ago as of this writing.  Much of the remainder of the market peaked in November 2021.

Viewed with this understanding, there is optimism that we may already be a good way through the fall.  The average bear market lasts just over 300 days, and the current sell-off has been uniquely difficult because of its long duration.  The S&P 500 declined for seven straight weeks beginning in March, the longest stretch of continuous losing weeks since 2001.

While market corrections are common – on average the market experiences a 10% decline once a year and a 20% fall once every six years – the last two market declines did not last long. The COVID-19 related bear market lasted only 33 days before bottoming and rising to new highs; and a nearly 20% correction that ended on Christmas eve in 2018 lasted only 90 days before starting a new rebound.  Investors can be forgiven for recent memories that corrections are quick and painless.  This time has been different.

The Fed remains committed to slowing inflation and will likely slow the economy with its actions.  Interest rates were increased again this week with expectations for more.   Their goal is to combat high inflation and prevent a wage-price spiral from taking hold.  Rising rates are intended to slow consumer and business spending, which should eventually have a downward impact on inflation, while also raising the risk of recession.

Much of the economic correction the Fed is seeking has already been accomplished.  Mortgage rates are higher, the housing and job markets have shown signs of slowing, and investors have certainly taken losses.  However, it is debatable if the Fed can manage an economic “soft landing” – the slowing of inflation without causing a recession.  Currently markets are pricing in a more recessionary outcome.

Bear markets that occur outside of a recession tend to be less severe and less lengthy.  Recessionary bear markets result in greater losses and a longer time before recovery.  If the economy avoids a recession, then we may be closer to the end of this bear market than the beginning.  If not, there could be more difficulties ahead.

Markets are unpredictable, but they are good at reminding investors that stock prices do not simply go up, uninterrupted forever. We know this is a difficult environment.  We believe the best strategy is to stay the course and focus on the long term, but every day one’s faith in the long-term is being tested.  Remember we have been here before.  We cannot know the precise timing or magnitude of bear markets, but history has taught us that the good times outweigh the bad.  As seen below, the S&P 500 Index has experienced 17 bear markets since its inception, and when bull and bear markets are viewed together, it is clear equities have rewarded disciplined investors over the long term.

Source: Dimensional Fund Advisors

FAMA/FRENCH TOTAL US MARKET RESEARCH INDEX 1926—12/31/2021: Fama/French Total US Market Research Factor + One-Month US Treasury Bills. Source: Ken French website

ProPhase Labs, Inc.: An emerging play in laboratory and genetic testing

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have a high conviction in their success; companies that are out of the mainstream of small cap investing. To highlight our process, we are pleased to present the newest installment in our new series “Marvelous Microcaps – Big Ideas on Small Companies.”  This series profiles companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

ProPhase Labs, Inc. (PRPH) is a provider of diagnostic services, OTC pharmaceutical products, and contract manufacturing services for third-party companies. Their diagnostics services consist primarily of processing COVID-19 tests through their wholly owned laboratory in Garden City, NJ. They also have a subsidiary called ProPhase Precision Medicine which was formed in August of 2021 in conjunction with their purchase of Nebula Genomics, Inc., a genetic testing company that sells kits online. Their consumer product lines primarily manufactures and markets nutritional supplements, sexual health supplements, and cold and cough lozenges.

The diagnostics business comprised approximately 87%  of their revenues for 2021.  This division was founded in October of 2020 in conjunction with the purchase of their initial laboratory in New Jersey to address the need for additional laboratory testing capacity as screening for the COVID-19 became more commonplace.  As testing increased, the Company built a state-of-the-art 25,000 square feet lab in Garden City, NY which became their new headquarters.  The outbreak of the Omicron Variant during this past winter led to that division growing revenues significantly as testing volume reached record levels. On a consolidated basis, the company reported revenues of $47.5 million in the most recent quarter, up from $15.3 million the previous year, an increase of 211%. They reported net income of $12.5 million and earnings-per-share of $0.81. They also announced a special dividend of $0.30 per share due to their strong results. Notably, just in the past two quarters combined, the Company reported $32.7 million in adjusted EBITDA on approximately 15.5 million shares outstanding. 69% of their testing revenues came from funding from the Department of Health Human Resources (HRSA) through a program for the uninsured. Funding for this program ended on March 22, 2022, and management stated on their most recent earnings call that due to this, revenues will be sequentially lower for the rest of the year, but each quarter will be higher on a year-over-year basis. There is also expected to be some seasonality with COVID-19 similar to the flu so testing revenues are expected to be higher in the winter than in the summer quarters.

WHY WE OWN: THE PERRITT ADVANTAGE

We own ProPhase Labs in both of our mutual funds and believe in the name due to their ability to position themselves strategically and execute in their marketplaces as demonstrated by their success in establishing a presence in two exciting markets with their COVID-19 and genetic testing capabilities. While there are some questions around the funding mechanism for uninsured patients through HRSA, the Biden administration is pushing for funding to be reinstated and the company is only accepting patients with insurance or that meet certain other criteria. This will mean lower revenues from that division for at least the rest of the year, but it likely will remain profitable with the goal to fund future growth opportunities for the company. The projected cash flow from this subsidiary along with approximately $21 million in net cash on their balance sheet sheet and over $50 million in net working capital should provide ample funding for their emerging growth opportunity in their genetic testing kits. While these kits are currently available online, ProPhase is working to sell them through their brick-and-mortar channels where they already have relationships through their other subsidiaries. Per commentary from CEO Ted Karkus during the recent earnings call, these tests provide the consumer with access whole genome sequencing.  This is a key differentiator for personalized health related information compared to more well-known offerings from Ancestry.com and 23andMe that provide more limited genetic information primarily used for ancestry analysis. They are intended to provide consumers with detailed information regarding their genetic makeup and any diseases or conditions they may be predisposed to. Once consumers have their results, they can learn more about each potential condition through an extensive library of information that ProPhase provides allowing them to get the information they need to both understand their results and discuss them with their healthcare provider. We believe that this new offering and its extension into brick-and-mortar retailers later this year will fuel the next stage of growth for the company. In addition, their healthy balance sheet reduces the risk of any capital raises taking place during these challenging times in the market.

We consider ProPhase Labs to be a high conviction name. It is currently a top ten holding for both funds and we are encouraged by their most recent results, their return of capital to shareholders in the form of a special dividend in March and June, as well as their commitment to continuing to drive growth through their purchase of Nebula Genomics and its future integration into their distribution network.

 

Perritt.  Marvelous Microcaps – Big Ideas on Small Companies.

 

Consumer Confidence and Microcap Stock Performance

Michael Corbett
CEO, CIO, Portfolio Manager

As the old adage says, a picture is worth a thousand words. The chart below shows how strong microcap performance can be in times following extremes in consumer sentiment. 

We have plotted the University of Michigan Consumer Sentiment Index readings over the past 50 years. You will see microcap stock returns marked for the 12-month periods following consumer confidence peaks and troughs. While the average consumer confidence reading is 86, the extremes dip to near 50 and rise to more than 110. 

Consumers can be a particularly moody bunch, but investors can be moodier. While most of the peak and trough points produced positive results for microcap stocks in the following 12-months, the degree of the returns is far stronger from trough periods. See for yourself. 

Consumer Confidence and Microcap Stock Performance

Chicago Atlantic (REFI)

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have a high conviction in their success; companies that are out of the mainstream of small cap investing. To highlight our process, we are pleased to present the newest installment in our new series “Marvelous Microcaps – Big Ideas on Small Companies”.  This series profiles companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

Chicago Atlantic (REFI) is a real estate finance company that is structured as a real estate investment trust, or REIT. A REIT is a pass-through vehicle, which means that the company does not pay federal income taxes if 90% or more of its taxable income is passed through to shareholders. This means that REITS often come with attractive dividend yields along with the opportunity for capital appreciation as their portfolio grows. While REIT investing is not a primary focus for us at Perritt, we will purchase one from time to time if we believe there is a unique value proposition to be had and we believe this is the case with Chicago Atlantic.

Chicago Atlantic lends to businesses in the cannabis space, in the form of senior loans secured by facilities and equipment. Due to the inconsistent nature of the United States’ cannabis laws, primarily the continued categorization as a schedule one controlled substance by the Federal government, banking in the space is difficult, with a limited number of firms serving the space. Most commercial banks that operate in states where cannabis is legal will not transact with businesses in the space due to the local and federal laws being at odds with each other; and since most banks operate in multiple states, they are regulated on the federal level. As a result, most businesses turn to the private lending markets for capital needs and Chicago Atlantic is one of those private lenders. Chicago Atlantic has operated for three years, reviewing over 500 loan applications and currently has 32 loans outstanding across 23 different portfolio companies. As of their last report dates March 16, 2022, loan commitments total approximately $324.2M. The company is new to the public markets, having completed their IPO last December to raise growth capital, all of which has already been committed to new loans.

WHY WE OWN: THE PERRITT ADVANTAGE

We took a position during the Initial Public Offering (IPO) in both of our funds based on our expectations that they would quickly deploy the additional capital that they raised from the IPO and subsequently raise their dividend as they received more money interest payments from a larger loan portfolio. During their last earning report in March, they reported an increase in their quarterly dividend payment from $0.26 cents per share to $0.40 per share, an increase of 53.8%. On an annualized basis this increase puts their forward dividend yield (the projected yield over the next 12 months) at 9%. We also believe that there are opportunities for capital appreciation in the stock price as the portfolio of loans grow.

We believe that the management team behind Chicago Atlantic has demonstrated a strong due diligence process, having reviewed over 500 applications, and maintaining a loan portfolio of 32 loans totaling $324M, with an additional $979 million in opportunities currently being evaluated in their pipeline. With the cannabis industry growing in multiple states as recreational legalization becomes more widespread, we believe that there is plenty of runway for Chicago Atlantic to continue to grow their loan portfolio with the same disciplined approach. Management recently stated on their conference call that they believe they are only in the second inning for the industry expansion due to the trends towards increased legalization across multiple jurisdictions. We also believe that their expertise in evaluating cannabis related loan applications, relationships with brand name cannabis firms, and pipeline of opportunities provide a competitive advantage over conventional commercial lenders in the event of banking legalization on the federal level.

We consider Chicago Atlantic to be a high conviction name with the caveat that cannabis space itself still is immature in many jurisdictions and that investing in the space comes with risks not found in other industries. Since purchasing Chicago Atlantic REIT in both funds during their IPO last December, we have subsequently added to name as initial results have confirmed our original thesis. We believe that the robust due diligence process they have in place, as well as their focus on the cannabis space will likely continue to allow for success in the future.

 

Perritt.  Marvelous Microcaps – Big Ideas on Small Companies.

 

Radiant Logistics, Inc.: Third-party logistics company providing multi-modal transportation and logistics services

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have high conviction of their success; companies that are out of the mainstream of small cap investing. To highlight our process, we are pleased to present the fifth installment in our new series “Marvelous Microcaps – Big Ideas on Small Companies”. This series profiles companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

Radiant Logistics, Inc. (RLGT) is a third-party logistics company providing multi-modal transportation and logistics services primarily in the United States and Canada. They offer domestic and international air and ocean freight forwarding services, freight brokerage services and other value-added supply chain services. Bohn Crain founded the company in 2005 to execute a consolidation strategy in the transportation and logistics sector. Bohn has extensive experience at Schneider Logistics, Inc., CSX Corporation, and other similar companies. In a world with a volatile shipping environment, Radiant provides best-of-breed services to their customers and partners.

Radiant has consistently focused on bringing value to the agent-based forwarding community. They enable their strategic operating partners to be equity owners in the business. They offer unique succession planning and liquidity opportunities for station owners. Their network participants benefit from RLGT’s increased purchasing power, expanding network of global trading partners and their ongoing investment in technology. Through their shipment tracking tools customers can know exactly where their products are at any moment.

WHY WE OWN: THE PERRITT ADVANTAGE

Radiant recently reported second quarter earnings that were stellar. Their industry has been hit with tight capacity and strong demand. New capacity is limited as labor shortages and tight supply chains keep new capacity from coming online. RLGT has had a history of growing both organically and by making acquisitions. They recently acquired Navegate which helps it expand its digital platform and manage international, cross border and domestic freight delivery. Their services include customs brokerage, international ocean and air freight forwarding, domestic truck brokerage, drayage and transload services. Navegate’s proprietary global trade management software platform has been recognized as the “Top 50 Logistics Companies in North America” * over the last several years.

Radiant’s balance sheet is under levered allowing them to make more acquisitions and buy back their stock. In the second quarter alone, they repurchased $4.6m of stock. RLGT plans to use roughly 50% of its free cash flow to repurchase more stock and make additional tuck-in acquisitions. Their stock remains cheap relative to their peers, trading at 4x AEBITDA. Radiant has a strong management team and slim cost structure will help enable them to possibly grow revenue and increase margins. In addition, some of their hard-hit verticals, such as trade shows and retail store fixturing are returning to normal allowing further growth.

 

Perritt.  Marvelous Microcaps – Big Ideas on Small Companies.

 

Interest Rate Hikes and Micro-Cap Stock Performance

Michael Corbett
CEO, CIO, Portfolio Manager

 One of the primary duties of the Federal Reserve is to foster economic conditions that achieve price stability. Over the past 12 to 18 months, the Fed has explained that the inflation we have been experiencing is short-term and transitory. They have maintained that price stability will return soon. In November 2021, however, the Fed abandoned the “transitory” statements, acknowledging longer-term inflation in the economy. What factors influence the Fed’s decisions and actions? In addition to raising the Fed Funds rate recently, we see several economic indicators that lead to the expectation that the Fed will raise the Fed Funds rate several more times. With the Consumer Price Index and the Producer Price Index reporting the highest increase in more than 30 years, some believe 6 or 7 increases are likely in the next year. 

The numbers tell the story, and they appear to be forcing the Fed to head back to their playbook. The question is: How do rising interest rates impact stock prices, particularly micro-cap stocks? In the table below, we assembled the past twelve periods when the Federal Reserve raised the Fed Funds rate. This data comes from the Federal Reserve Economic Data (FRED). As you can see, the average length of time the Fed raised rates was 24 months, with the least time being 6 months and longest being 53 months. We also included the range of increases which include a modest increase of rates from 4.75% to 6.54% in the 1999/2000 period to a drastic increase of 4.61% to 17.61% in the 1977/1980 period. 

We then gathered the micro-cap performance from the Duff & Phelps’ Ibbotson Annual Yearbook. The performance results are from the month-end date when the Fed raised rates until the month-end when they stopped raising rates. As you can see, micro-cap stocks rose in ten of 

the twelve periods when the Fed raised rates, and the average gain was more than 25%. There are two notable periods I would like to address. First, the 1972 to 1974 period certainly was a negative period for micro-cap stocks with a 40.61% decline, but that period was also plagued by other social and severe economic factors. However, the second period to note is 1977 to 1980 which was also affected by several social and economic factors. Although inflation was severe in the late 1970s, the strength of the economy drove the performance of micro-cap stocks to an exceptional gain of nearly 84%. We believe that the current economic situation could be like the second period. While inflation is part of the picture, we expect that the strength of the economy could drive robust performance for micro-cap stocks. 

MarketWatch Interview

By Michael Brush

If the huge downside volatility in large-cap darlings such as Netflix and Facebook have you queasy, here’s a potential alternative: Go small.

Small companies have already been beaten up in the rolling market correction since last summer. So much so, they now look cheaper than they have in decades, despite solid growth.

Here are three reasons you should consider smaller companies now, and seven names that have good potential, according to experts in the space.

Reason #1: They look cheap

Relative to large-cap stocks, small-cap and mid-cap stocks — known in the industry as smidcaps — have only ever been cheaper once before in recent history. That was during the tech bubble. Using forward earnings, their price-to-earnings (P/E) ratio is currently around 0.7 that of larger-cap stocks. That’s the lowest since this ratio nearly touched 0.6 in 2000, notes James Paulsen, an economist and the chief market strategist at Leuthold.

The smaller names of the S&P 600 trade at 14.5 times forward earnings vs. 20.2 for the S&P 500. Smidcaps also trade in line with their historical valuations.

Despite this relative discount, smidcap earnings are currently going up a lot faster than large-cap earnings, says Paulsen. But they get no respect.

“Their businesses have expanded. But they have not gotten a multiple expansion,” says Perritt Capital Management’s Michael Corbett, who specializes in small-cap investing. “They have had multiple contraction.”

Here is a visualization of what Paulsen and Corbett are talking about, from Bank of America.

“Small-caps now trade at a historical discount to large-caps on every valuation metric we track,” says one Bank of America analyst.

“This period reminds me of the late 1990s and early 2000s when it only made sense to buy large-cap and dot-com names,” says Corbett. “At some point, investors could not justify the prices anymore.”

We may be seeing the beginning of that now, given the recent stunning declines in Netflix and Facebook shares, on weaker-than-expected business trends and guidance.

Reason #2: Smaller companies have done better in a strong economy

Despite worries about recession because the Federal Reserve will be raising interest rates, the economy will likely be strong this year due to various types of embedded stimulus, predicts Paulsen. This includes low inventory levels that need to be raised, and strong consumer and corporate balance sheets.

Smidcap companies have outperformed when there’s growth for several reasons. First, they can raise prices, which boosts margins. Since smaller companies tend to be leaner, more of the pricing gains fall to the bottom line.

“Inflation could change the dynamic,” says Corbett. “They are behind the curve on raising prices, but they will likely catch up. The margins and earnings profile could look dramatically better.”

Next, smaller companies tend to be based in cyclical businesses, and cyclicals have done better when the economy is strong, says Corbett. They were also hit harder by the COVID-related lockdowns, in part because they usually have less diversified businesses, says Tyler Laundon, chief analyst at the Cabot Small-Cap Confidential stock letter. This means they have more room to improve as COVID recedes and the economy gets back to normal.

Reason #3: Consumer confidence will likely increase

Consumer confidence is low. But I think it will improve as it becomes more apparent that Omicron marks the end of the pandemic, as inflation eases, and as more people find jobs and get more pay hikes. Historically, smidcap stock performance shows a strong correlation with consumer confidence, says Paulsen. As confidence increases, people consider riskier investments — like smidcaps.

Stocks

To find names, I consulted experts in this space. Besides Corbett at Perritt Capital Management and Laundon at Cabot Small-Cap Confidential, I checked in with Bruce Kaser at Cabot Turnaround Letter, a value investor who goes into the smidcap space.

Lamb Weston

Market cap: $9.4 billion

If you order fries with your meal, you’re probably a customer of this company. Lamb Weston is a big supplier of frozen fries cooked up in restaurants. Based in Idaho (of course), this company sells to the top 100 restaurant chains in North America and overseas, including McDonald’s. You can also find its spuds in grocery stores.

The company has been posting strong sales growth, but earnings have been hit by inflation and supply chain problems. These should turn out to be temporary issues. “The company is well-managed, has a strong market position, generates healthy profits and cash flow, and should eventually resolve its cost problems,” says Kaser at Cabot Turnaround Letter. I suggested this one in my stock letter Brush Up on Stocks at around $57 in early November. It’s now up 13% compared to a 2.7% decline for the S&P 500.

WildBrain

Market cap: $402 million

WildBrain manages content and consumer licensing for popular brands like Peanuts, Teletubbies, Strawberry Shortcake, Caillou and Inspector Gadget. Revenue increased 18% in the third quarter. The Canadian company plans to continue to grow by rolling out new consumer products and content. For example, it recently signed a deal with Apple TV+ for the production of a new “Yo Gabba Gabba!” series, and access to historical content. This follows a similar deal that put Peanuts on the Apple platform. It also recently signed a deal with Moose Toys to roll out new toy sets. “Revenue growth should be better than expectations,” predicts Corbett.

Infrastructure and Energy Alternatives

Market cap: $436 million

This infrastructure construction company specializes in wind and solar energy projects. But it also does design, construction and restoration of roads, bridges and industrial infrastructure. The stock got ahead of itself by early last year on excessively bullish sentiment, but it has fallen 60% since. Yet revenue growth looks solid. Third-quarter sales grew 37% and the company raised 2021 sales guidance to $2.1 billion at the high end, from $1.95 billion. The company should benefit from the recent federal infrastructure bill, says Corbett.

Shutterstock

Market cap: $3.4 billion

Shutterstock runs an online marketplace for digital photos, video footage and music. Contributors upload content and earn royalties on sales. Users typically put the content in marketing materials, media content and games. Third-quarter sales grew 18%. Shutterstock does well in part because it is huge, says Laundon. It features over 1.9 million contributors who have added more than 390 million images and 23 million footage clips. It has over 2 million active paying customers.

Legacy Housing

Market cap: $633 million

The housing market is hot. Energy prices keep going up. This company potentially offers a way to benefit from both trends. Legacy Housing sells manufactured homes and “tiny houses” that cost $22,000 to $140,000. It does nearly half its business in Texas, which makes this an energy play. Concerns about rising mortgage rates (priced off the 10-year government bond yield) are an overhang, but Corbett doesn’t see this as an issue. “You would have to have interest rates skyrocket for real problems to happen,” he says. He thinks the 10-year bond yield could rise to 2.25% by year-end, and that won’t be enough to kill demand. Third-quarter sales grew 29%.

Xometry

Market cap: $2.1 billion

This company operates a digital marketplace serving the $260 billion industrial manufacturing industry. Its platform helps manufacturers get instant quotes on parts. It wants to be the Amazon.com of this archaic market, but with a high-tech twist. Buyers can upload 3D design files with detailed specs when shopping for parts.

Xometry launched in the U.S. nearly 10 years ago. Now it’s expanding into Europe and Asia, notes Laundon, who says Xometry is well-positioned to turn this business on its head. The company has guided for 63%-66% fourth quarter sales growth. Active buyers increased 61% in the third quarter.

Photronics

Market cap: $1.1 billion

You’ve heard about the chip shortage. Photronics may benefit. It sells glass plates with images of electronic circuits used to make chips. These photomasks help chip makers put circuit patterns on semiconductor wafers. The chip shortage has increased demand for its product. In the fourth quarter sales grew 6% sequentially and 21% year over year, in part, because of newfound pricing power. “That is what has changed. The margins are likely going to improve,” says Corbett.

Quest Resources: One person’s garbage is another’s treasure!

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have a high conviction in their success; companies that are out of the mainstream of small cap investing.  To highlight our process, we are pleased to present the fourth installment in our new series “Marvelous Microcaps – Big Ideas on Small Companies”.  This series profiles companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

Quest Resources (QRHC) is a provider of waste management services to businesses in the Fortune 1000 space.  Operating as an “asset-light” provider of services, Quest is an outsourced managed services provider for their customers.  Utilizing a proprietary technology platform, they analyze the needs of their customers and find the best local providers of waste management services to address customer’s needs.  The majority of their business is driven by the recycling and disposal of regulated waste streams: such as food, construction, and automotive waste, hazard chemicals and general recycling.  While a private residence may rely on municipal waste services to collect their trash from the curb once a week, most municipal sanitation providers do not service private businesses nor regulated waste streams necessitating the use of commercial providers of these services.  By targeting the Fortune 1000 market, Quest Resources are servicing clients with complex requirements.  In fact, their average customer has five different waste streams spread out across multiple locations which requires the use of multiple service providers.  Quest’s business proposition is that they take over the waste management needs of a portion or all of a company’s locations, aggregating the services under the Quest umbrella.  From that point, they will find the best service provider for each waste stream in the local area and outsource the physical disposal to that provider.  The value add to their customers is that they do not need to find these providers themselves and they do not have to handle multiple invoices for waste removal.  In the case of regulated waste streams, Quest helps to provide an audit trail for businesses to use in the event regulators need to see records for compliance purposes.  While Quest mainly utilizes third-party service providers, they will operate their own waste management services in certain verticals in geographies where they have significant customer concentration.

WHY WE OWN: THE PERRITT ADVANTAGE

Today Quest is a top holding for the Ultra MicroCap Fund and has been recently graduated to the MicroCap Opportunities fund, however, the origin of our research in the name goes back to 2014.  At that time, the company had grown revenues significantly from $67 million in 2013 to $174 million in 2014.  However, the previous management team achieved this growth by underpricing their services and losing money on new contracts.  These poor operating results led to a steep sell off in the company’s stock which necessitated the hiring of a new management team led by current CEO Ray Hatch.  Under Ray’s leadership, the company extricated themselves from the money losing contracts signed by the previous management and began the process of building out their technology platform and reorganizing their sales force.  Perritt initiated a position when the initial results from their internal initiatives began to show improvements in the company’s prospects.  Today, these efforts have paid off, with gross margins* more than doubling in the past five years from 7.8% at the end of 2016 to 18.7% on a trailing twelve-month basis as of the most recent quarter.  The improved margins along with prudent management of other corporate expenses have allowed Quest to go from a money losing business to a profitable business that is ready for the next phase of expansion.

With the turn-around behind them, the firm has begun to focus on future growth.  They recently completed a series of acquisitions in 2021 that saw them purchase four waste management companies throughout the continental U.S.  These acquisitions bring some of the services that Quest has been providing their customers in house which will allow them to capture additional margin growth as they capture more of their customer’s dollar spend.  With the company now profitable, they have the ability to consistently generate cash to pay for further growth through acquisitions while continuing to grow organically by leveraging their internal sales force and technology platform.

We consider Quest Resources to be a high conviction name.  The name is a top ten holding for the Perritt Ultra MicroCap Fund and was added to the Perritt MicroCap Opportunities fund last year as results improved.  We are optimistic that they have the right technology, service offerings and most importantly, leadership to drive their success going forward.

*Gross Margins represent the percentage of revenue that remains after accounting for the direct costs of selling a product or service.

 

Perritt.  Marvelous Microcaps – Big Ideas on Small Companies.

 

iCAD, Inc.: Breast cancer detection solutions built on artificial intelligence

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have high conviction of their success; companies that are out of the mainstream of small cap investing. To highlight our process, we are pleased to present the fourth installment in our new series “Marvelous Microcaps – Big Ideas on Small Companies”. This series profiles companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

iCAD (ICAD) operates through two segments, Cancer Detection and Cancer Therapy.  Their advanced breast cancer detection solutions are built on artificial intelligence that enable radiologists to find cancer earlier and faster.  Their Breast Health Solutions suite operates in 2D and 3D and rapidly and accurately analyzes each image detecting both malignant soft tissue densities and calcifications with unrivaled accuracy.  The company’s ProFound AI Risk product works with 3D mammography and is the first and only clinical decision support tool to estimate breast cancer risk for each woman. This will move the breast mammography industry from age-based screening to risk-based screening leading to both prevention and treatment of breast cancer.

With their innovative technology, they expanded the breast cancer detection to also detect and treat other cancers.  Xoft Brain IORT recently treated the first patient with glioblastoma (brain cancer).  Xoft is FDA-cleared and licensed for the treatment of cancer anywhere in the body.  It used the world’s smallest X-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site thus targeting only the cancer cells and not damaging nearby healthy cells.  IORT and Xoft allow oncologists and surgeons to deliver a full course of radiation treatment in one day, at the time of surgery, while the patient is already under anesthesia.  Other cancers that can be treated are non-melanoma skin cancer, Endometrial, and cervical cancer.

WHY WE OWN: THE PERRITT ADVANTAGE

The marketplace in breast imaging for this product is huge and largely untapped.  Approximately 20% of breast cancers are not detected and traditional mammograms generate many false positives.  ICAD’s product operates more efficiently, accurately, and faster.  The current install base is about 1350 units marketed by a sales force of only 13.  The Therapy segment’s potential is huge to treat many types of cancer in the operating room removing the need for many sessions of radiation.  The platform also provides for a razor-razorblade model resulting in recurring revenues.

Third quarter of 2021 had 31% revenue growth which missed analysts’ estimates by $500,000.  The stock has fallen more than 30% providing a great buying opportunity.  They have cash of $35.8 million which should be sufficient to fund their future growth. A new CEO was appointed in December and Insiders have bought stock recently.

ICAD traded at a little more than 3 times 2022 sales estimates which reflects 30% growth with 72% gross margins.  They have been affected by Covid-related slowdowns in procedures, which we believe will increase as the effects of the COVID pandemic diminish.  They have been aggressively pursuing subscription offerings which will likely increase recurring revenues.  This is a stock that has disruptive technology and is currently selling at bargain bin prices.

 

Perritt.  Marvelous Microcaps – Big Ideas on Small Companies.

 

Michael Corbett visits Fortitude Gold (FTCO) mine

 

Fund holdings and sector allocations are subject to change at any time and should
not be considered a recommendation to buy or sell any security.  For the top ten
holdings for the Perritt MicroCap Opportunities Fund please click PRCGX and
PREOX  for the Perritt Ultra MicroCap Fund.

Identiv: A specialty security company venturing out into new horizons

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have a high conviction in their success; companies that are out of the mainstream of small cap investing. To highlight our process, we are pleased to present the second installment in our new series “Marvelous Microcaps – Big Ideas on Small Companies”. This series profiles companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

Identiv, Inc. (INVE) is a technology company operating in the security space specifically addressing needs around physical and logical access to secure sites and identity verification for access and cyber security purposes. In addition to that they provide asset tracking, archiving, and monitoring products. The company sells both hardware and software on a contract and subscription basis. They market their products through a diversified network of distributors, security system integrators and value add resellers. In addition to their core security markets, the company has leveraged their expertise in radio-frequency identification (RFID) technology to expand use into several other markets where asset tracking and verification needs were not being sufficiently met, opening several new market opportunities for their products in an increasingly networked world.

Identiv, Inc. offers a wide variety of products including hardware for controlling access to secure facilities such as government facilities, corporate facilities, schools, and apartment buildings. These range from the ubiquitous number pads found on many secure entry points to state-of-the-art passive, touchless RFID readers that allow for frictionless entry for authorized individuals while preventing access to those without authorization. The company offers products in the video surveillance space that include features such as facial recognition, vehicle recognition and object identification/tracking. This data is then stored for future use as indexed records for their customers and as real time data around occupancy and utilization. The core competencies of the company in the security space have given the company substantial expertise in the development and use of RFID technology. The key long term growth driver for the company is leveraging their expertise to expand its use in the security space as well as its deployment in other industries.

WHY WE OWN: THE PERRITT ADVANTAGE

We own Identiv in both mutual funds and the investment thesis is based on the growth prospects of the company, their patent portfolio, and the strength of the company’s financials. The company has leveraged their expertise in security focused RFID technology to bring the technology to other verticals. As an example, CVS Pharmacies uses Identiv’s RFID technology in their labels to enable a program called Spoken Rx™ , designed for consumers with visual impairment to scan any prescription label with their phones to receive an audio readout of their prescription. They recently announced the rollout of this program in all CVS locations nation-wide. In other use cases their labels have been used on prefilled syringes in healthcare settings to track the time, place and medication used in injections and been used to track blood samples in laboratory settings. Outside of healthcare, Nike has installed Identiv’s tags inside of some of their shoes. These tags can provide consumers with additional features and serve as verifications of authenticity which can be popular with collectors. The company also has sold their technology and services into the cannabis space with a recent contract award from a customer for an initial order of 20 million units. To date the company estimates their devices have been installed on 1.5 billion physical objects worldwide with the market potential for networked devices being in the hundreds of billions.

The company has a substantial portfolio of 36 different patent families as well as additional trade secrets. Their ability to design products around their customer’s needs has led to over 150 antenna designs and in-house RFID designs. We believe that this background gives them an advantage over competitors that do not offer the same high-touch level of service and expertise and serves as a defensive moat around the company’s business model. The company recently paid off all their outstanding loans and is now debt free with $29.2 million in cash available to fund their internal growth needs as well as potential acquisitions.

We consider Identiv to be a high conviction name.  At the close of the most recent fiscal year ending October 31, 2021, the Ultra MicroCap Fund had a weighting of 1.74% of assets and the MicroCap Opportunities Fund had a weighting of 0.87% versus only 0.05% in the Russell Microcap Index. We believe the company is in the early innings of a multi-year market expansion driven by the growth of RFID use around the world and based on fundamental analysis, Identiv could be a successful, long-term player in the space.

 

Perritt.  Marvelous Microcaps – Big Ideas on Small Companies.

 

Co/Investor Club Microcap Managers List

Matt Brackmann,
Perritt Capital Management

The next feature of our Top 50 Micro-cap Manager list is Matt Brackmann. “Matt joined Perritt Capital Management in 2004. As portfolio manager for the Perritt Ultra MicroCap Fund, Matt is actively involved in idea generation and company research. Matt also serves as an equity analyst for the Perritt MicroCap Opportunities Fund. As Director of Trading, Matt is responsible for overseeing the firm’s trading desk, which includes overseeing all trading activity for advisor clients, keeping and maintaining trading records, arranging and managing relationships with sell-side brokerage firms, and serving as the liaison between the advisor and the advisor’s client custodians. Additionally, he is a Registered Investment Advisor and received his B.B.A. in Finance from the University of Iowa in 2004.”

The microcap fund under management typically holds anywhere from 70-80 securities with the largest weighting reserved for the tech sector. Now you might imagine the difficulty of trying to validate 15 or more investment theses continuously, yet Matt manages to break each thesis down in a strikingly simple manner. For example, Turtle Beach (HEAR) was trading near $5 early in the pandemic. The company had not met analyst expectations for some time, so the stock price had been sliding prior to Covid-19’s outbreak. The fund Matt manages purchased some shares and has enjoyed a nice ride up to $28. Or as Matt humbly put it, “it didn’t take a big leap to understand that people would stay home and spend [more] money on gaming” throughout Covid-19. While Matt has drawn inspiration from many people including Marcus Aurelius, who wrote “Meditations,” his greatest inspiration came from his mom. While growing up on a farm, nearby his mother worked at JP Morgan Chase which ultimately had a major influence over the direction of Matt’s career.

We are excited to introduce Matt as the latest addition to our Top 50 Managers list and include him as a part of our network.

Click here to view PDF.

2021 Distribution Update

The Perritt MicroCap Opportunities Fund and the Perritt Ultra MicroCap Fund paid a long-term capital gains distribution on 11/23/21 to shareholders.

• The long-term capital gains distribution in the Perritt MicroCap Opportunities Fund (PRCGX) was $4.12564 per share and $1.36876 per share in the Perritt Ultra MicroCap Fund (PREOX).
• Any income or short-term gains in our Funds will be paid on 12/28/21 to shareholders of record on 12/27/21.

Long-Term Capital Gains distribution:

 

Please visit our website at www.perrittcap.com/index.php or call 1-800-331-8936 for more information. Thank you for your investment and trust in the Perritt Team.

Click here for research and insights regarding small company investing.

Click here for a prospectus.

ImmuCell – An “Udderly” exciting name in the animal health space

INTRO:

At Perritt Capital Management, we take focused positions in companies where we have a high conviction in their success; companies that are out of the mainstream of small cap investing.  To highlight our process, we are pleased to present our new series “Marvelous Microcaps – Big Ideas on Small Companies”.  This series will profile companies that we believe have a niche in their existing markets or are launching a product that could disrupt their marketplace.

THE COMPANY:

ImmuCell Corp. (ICCC)¹ is an animal health company headquartered in Portland, Maine. ImmuCell develops and manufactures products addressing common infections that occur in dairy and beef herds. They market these products through an internal sales team spread throughout the United States and Canada, and internationally through distribution partners.

ImmuCell has one primary product line in the marketplace today called First Defense®. First Defense® is the only USDA-approved orally administered scours preventative with claims against three major infections that impact dairy cows.  Scours is a leading cause of infections in dairy calves and costs the industry approximately $740 million dollars a year.  First Defense® has the advantage of reducing waste by being administered to only viable calves and reducing unnecessary vaccinations being given to the mother.  The company is also pursuing regulatory approval for a new product called Re-Tain™ to address an underserved market in sub-clinical mastitis infections that can’t be addressed by existing anti-biotics.  Mastitis is an infection of a cow’s mammary glands that at clinical levels prohibits the cow from producing commercially viable milk.  In any given year it can impact 20-25% of a dairy herd. ImmuCell’s Re-Tain™ is intended to address infections at the pre-clinical level, meaning prior to the infection being so severe that the animal is removed from the milking herd.  They accomplish this by using an active ingredient that does not require the cow be removed from the milking herd during treatment because unlike the current standard of care, the active ingredient is not an anti-biotic also used in humans.

This is the first of our ongoing “Marvelous Microcaps – Big Ideas on Small Companies” series.

WHY WE OWN: THE PERRITT ADVANTAGE

We view the competitive advantage for ICCC to come from three different characteristics:  They have a set of product lines differentiated from the competition in terms of the pathologies they address and the active ingredients used, they have products that are more targeted in their treatment methodologies which reduces waste and ultimately provides great economic benefit to their customers, and they have invested in a new product line that could change the market for mastitis treatment in that it addresses the problem before the animal is clinically infected and has to be pulled from the milking herd and be treated with anti-biotics.  Currently, mastitis costs the dairy industry $2 billion per year and Re-Tain™ could help lower those losses to farmers, thus making it a disruptive entry into its marketplace. The company expects a decision on regulatory approval to take place in the second half of 2022.  The company has made significant investments in both their manufacturing capabilities as well as their sales and marketing efforts in the last several years and that growth is showing in their numbers.  In the most recent quarter ending September 30, 2021, they reported revenue growth of 38% of a year-over-year basis.  Based on our own research including years of dialogue with management, we believe that they have the opportunity to disrupt the standard of care in their end market with the launch of Re-Tain™.

We consider this a high conviction name, and it is a top ten holding as a percent of fund assets in the  Ultra MicroCap Fund, currently standing at 2.0% as of October 31, 2021 versus making up just .01% of the Russell Microcap Index.  ImmuCell currently does not have any analyst coverage from a major research firm, and we believe that may be due to the esoteric nature of their markets that it has so far escaped the attention of much of the investing public.  With the additional expected product line and the increased resources allocated to marketing their products, we believe that ImmuCell is a unique, potentially disruptive, and undervalued investment in the animal health and wellness space.

ImmuCell gives shareholders in our MicroCap Funds exposure to Perritt’s active, fundamental bottom-up process and portfolio management versus a passive investment in a Microcap Index.

 

Perritt.  Marvelous Microcaps – Big Ideas on Small Companies.

 

2020 Distribution Update

We do not anticipate a capital gain or income distribution this year for the Perritt MicroCap Opportunities Fund or the Perritt Ultra MicroCap Fund.

Please visit our website at www.perrittcap.com/index.php or call 1-800-331-8936 for more information.  Thank you for your investment and trust in the Perritt Team.

Click here for research and insights regarding small company investing.

Click here for a prospectus.

 

Manager Commentary, 2nd Quarter 2020

Wall Street and Main Street Get a Divorce

Wall Street and Main Street have gotten a divorce, or at the very least they have separated.  The U.S. is in a recession but the stock market marches blindly higher.  In most people’s lives we have never seen such a confluence of dangers: Depression levels of unemployment, the economy in a downward spiral, prevalent rioting and unrest, and an imminent second wave of the virus.  Yet the stock market continued upward and celebrates information, such as jobs data that is slightly misleading.  The S&P 500 has had the biggest rally in its history.  It plummeted 34% from its mid-February high to bottom on March 23.  It has since rocketed up 43%.

We have long been told that the market is forward thinking, and the economy looks backward.  But these are unprecedented times.  Economic data has surprised to the upside but has already lagged again making the data stale almost immediately. Uncertainties, which the market hates, are in abundance.  Will states shut down again (as some are already doing)?  When will a vaccine be available?  How many businesses will permanently close?  Will generous unemployment benefits and another stimulus be extended?  And the big looming question, who will win the Presidential election in November?  Many small businesses, which have been hit the hardest, are not publicly traded so they are not reflected in the market.  We seem to be a market of wishful thinkers, but if just one of the cogs in the wheel fails to work, what are the implications?  Has the market taken that all into account?

An explanation for a continued bullish market is that the worst is behind us and the economy will rebound quickly.  FOMO (fear of missing out) is at play here.  Who wants to miss out on performance like we have seen the last 10 years?  We also locked a population down with nothing to do, no sports to watch, no casinos to go to, and then put a stimulus check in their pockets. Robinhood, which caters to amateur traders, reported a record 3 million new accounts in the first quarter.

Robinhood Data Shows a Leap in Retail Investor Trading Activity

Another explanation is TINA – There Is No Alternative. Low interest rates have made bonds and money market accounts unappealing, so excess cash has been plowed into the stock market.

Going forward, we are skeptical.  The market hates uncertainty and we have an abundance of it.  A market dealing with uncertainties is nothing new but an overvalued market dealing with foreboding economic data among so many other factors is new.  Will Wall Street and Main Street reunite?

Given what we are all living with today, here is a great perspective

It is a mess out there now. Hard to discern between what’s a real threat and what is just simple panic and hysteria.  For a small amount of perspective at this moment, imagine you were born in 1900.

On your 14th birthday, World War I starts, and ends on your 18th birthday. 22 million people perish in that war.  Later in the year, a Spanish Flu epidemic hits the planet and runs until your 20th birthday.  50 million people die from it in those two years.  Yes, 50 million.

On your 29th birthday, the Great Depression begins.  Unemployment hits 25%, the World GDP drops 27%.  That runs until you are 33.  The country nearly collapses along with the world economy.

When you turn 39, World War II starts.  You are not even over the hill yet.  And don’t try to catch your breath.  On your 41^st birthday, the United States is fully pulled into WWII.  Between your 39th and 45th birthday, 75 million people perish in the war.

Smallpox was epidemic until you were in your 40’s, as it killed 300 million people during your lifetime.

At 50, the Korean War starts.  5 million perish. From your birth, until you are 55 you dealt with the fear of Polio epidemics each summer.  You experience friends and family contracting polio and being paralyzed and/or die.

At 55, the Vietnam War begins and does not end for 20 years.  4 million people perish in that conflict.  During the Cold War, you lived each day with the fear of nuclear annihilation.  On your 62^nd birthday you have the Cuban Missile Crisis, a tipping point in the Cold War.  Life on our planet, as we know it, almost ended.  When you turn 75, the Vietnam War finally ends.

Think of everyone on the planet born in 1900.  How did they endure all of that?  When you were a kid in 1985 and did not think your 85-year-old grandparent understood how hard school was.  And how mean that kid in your class was.  Yet they survived through everything listed above.

Perspective is an amazing art.  Refined and enlightening as time goes on.  Let us try and keep things in perspective.  Your parents and/or grandparents were called to endure all of the above – you are called to stay home and sit on your couch

Maybe we don’t have it that bad?

This too shall pass.

Perspective is meaningful.

Manager Commentary, 1st Quarter 2020

A GLIMMER AMONGT THE DOOM AND GLOOM

To say these are unprecedented times would be an understatement. Fear and despair are at the forefront of all our news. Rather than recap all the COVID-19 news, we thought we would take the high road and remain optimistic. We believe the best time to find investments is when everyone else is turning away. To quote one of our favorite leaders, Winston Churchill, “Never give in – never, never, never, never in nothing great or small, large or petty, never give in except to convictions of honor and good sense. Never yield to force; never yield to apparently overwhelming might of the enemy.”

Part of our optimism is due to the belief that active management appears to be coming back in favor. We believe active management will beat index-tracking funds as the global meltdown has led to a dislocation between price and value. We are seeing it with the large cap stocks, where 60% of actively managed mutual funds that buy large cap stocks beat the Russell 1000 in February. They outperformed across core, value and growth investing styles. New actively managed ETFs debuted at the end of March, allowing managers to pursue their strategies without fear of being copied.

Active managers have historically outperformed their stated indices during selloffs and other periods of volatility when they identified outperformers and mitigated the downside. Passive investments have almost total exposure to the performance of a benchmark index – both when it is rising and when it is falling. The following two charts show the outperformance of active investing versus passive investing in both the Dot.Com Crash and the Global Financial Crisis.

We believe stock-picking is making a comeback. There is no substitute for evaluating a company and how it performs in extenuating circumstances. After the world calms down, there will be a new normal, and choosing the right stocks for that environment should be invaluable.

The past quarter was painful for both active and passive investors. The equity markets, particularly small stocks, had the worst quarter since the 2008 bear market and the great depression that started in 1929. As was said earlier, these are unprecedented times, mainly because the economy is shut down for the most part. While it is imperative for most us to stay home to save lives, the economic ramifications are enormous. To help the economy and most workers, the Federal Reserve and the Federal government launched the largest stimulus in our history, which we agree is justified. However, the long-term economic consequences will be very costly. As of quarter end, the Federal Reserve has not only reduced interest rates to zero but added more than $6 trillion of liquidity to the economy. The Federal government is in the process of adding more than $2 trillion to the economy and will likely add more soon. These two packages represent more than a third of the U.S. economy’s annual GDP (Gross Domestic Product). As our leaders and the POTUS (the President) prepare to evaluate and present a plan to return to work and life as we once knew, the future will likely be very different for both individuals and businesses. Because of those differences in the future, we have a different sense of optimism for active management and small stocks. We expect many differences in the years ahead. Here are a few that we think will benefit small stocks.

As investors in small companies, we have always been aware of the challenges of raising capital. Capital has been available for small companies, but we would argue the cost has been egregious for most in the past decade or so. A decent part of the capital the Federal Reserve and the Federal government are putting into the economy are low cost loans. A large part of these loans will be just enough for some companies to survive. However, there may be several small companies where these loans may help them thrive in the future. Another change we see is less stock buyback programs. It seems clear to us that future stock buyback programs may be frowned upon. While buybacks can be a useful tool for capital, it is hard to argue that they do not help economic growth or job growth. If the economy and stock market were so strong in the past ten years, why did our economy not grow much above 2% annually? We are in the camp that the past tax cuts mostly benefitted larger companies and those cuts were largely used for stock buybacks. The bottom line is that we believe capital will be used to grow the economy and create jobs, and less for stock buybacks.

There are other benefits for smaller companies, but we believe the biggest change will be in the change of attitude. Small companies employ the majority of our workforce. The number of people applying for and collecting unemployment is skyrocketing every week. Most unemployed worked for small companies. We expect, as a nation, we will encourage our leaders to help smaller companies and their workers. We expect future policies that will benefit smaller companies and not just large companies as we saw in the past. In the meantime, there will likely be more challenges for investors. Below are some updates on our micro-cap portfolios that make us believe these companies will survive and likely thrive in the future.

In the past few weeks, we have had discussions with management from all our portfolio companies. A small group of them have issued updates on their businesses and, for the most part, withdrew any guidance for 2020 results. It is likely that the rest of our companies and most public companies will withdraw 2020 guidance soon. It will be interesting to see how the markets react to these announcements, but we remain optimistic that investors will focus the potential results of 2021 and beyond. Our recent conversations with management were about not only long-term prospects, but the near-term challenges as well, particularly whether they can withstand an extended shutdown of the economy. We are happy to report that most are very confident that they will survive and thrive. While there were about a half dozen that still concerned us, those management teams assured us they will have the resources to survive.

Below is a table that gives us confidence these companies will survive this shutdown and can thrive in the future. As you can see, on average, companies in our portfolios are less leveraged than companies in the Russell Microcap, Russell 2000 and the S&P 500 Indexes. We also have more companies with no debt on the balance sheet than these indexes. Between our two microcap strategies, we have a dozen that trade at or near net nets. This means that the company’s market capitalization is less than the company’s current assets less all liabilities. A great deal of these current assets are cash. Lastly, nearly a quarter of our companies paid quarterly cash dividends and all but two have dividend yields above the 10-year government yield. Thank you for reading our commentary. We hope you and your family are safe and healthy. While the last quarter and even the past few years has been challenging for micro-cap investors, we continue to have a glimmer of hope for micro-cap companies.

 

Manager Commentary, 4th Quarter 2019

PARTY LIKE IT’S 1999

The longest bull market in history keeps rolling along. And the recipients of this bull market’s run are losing money hand over fist. There are more than 40% of listed companies in the U.S. that lose money – the highest level since the late 1990’s outside of post-recession periods. 42% of those money losing companies are health care and 17% are technology companies. Approximately less than a quarter of the companies that went public in 2019 will have positive net income – the lowest level since the tech bubble. Like the tech bubble in 1999, investors are pouring money into tech and now health care. Last year investors put $11 billion into digital health companies. Venture capital funding has reached the dot-com era level. According to research firm Preqin, private equity firms have amassed approximately $1.5 trillion in unspent capital, the highest total on record.

This isn’t the only characteristic that is like the tech bubble. The Fed’s open checkbook is making many observers worried. There is extraordinary liquidity being provided by the world’s central banks, which is flowing to the most liquid and largest names in the S&P 500. This reminds us of 1999, when the Fed expanded the balance sheet at the end of the year and early in 2000 as a precaution against a Y2K disruption. The Fed supplied about $120 billion to the market through repos to prevent a disruption then. This was about the same amount pumped in during the financial crisis of 2008 and more than it provided in reaction to the September 11 attacks. Since October of last year, the Fed has supplied approximately $400 billion in four months – a $1.2 trillion annual rate!!

This liquidity is feeding into large, liquid names – the bigger the better. As seen by the Fear & Greed Index below, the greed reading is at 89 down from 93 a week ago. We believe this is FOMO (Fear Of Missing Out) at its best.

FEAR AND GREED INDEX
What emotion is driving the market now?

Here is another data point to think about. There are currently 82% of companies in the S&P 500 Index trading above their 200-day average price, the highest percent in 2 years. A senior trader and market technician at Instinet said the last time so many companies were above this level, a correction followed not long after. According to Chuck Royce, over the last 20 years the 50 biggest stocks in the Russell 3000 Index have averaged a combined total market cap of about four times the total market cap of the Russell 2000. At the end of 2019, that ratio was more than six times – higher than it was at the height of the internet bubble in 2000.

Are we beginning to sound like a broken record? This may not be the makings of a bubble, but it’s the closest thing we have seen to one in a long time. If this is another bubble, the market overall could be in for a rough ride soon. While microcap stocks may get hurt if this bubble pops, we would argue that the damage would be significantly less and the rewards following the carnage could be material. As we have shown in past commentaries, microcap stocks are selling near their largest discount to large-cap stocks in decades. While past performance is no guarantee of future results, this market reminds us a great deal of 1999. The performance table below shows how our MicroCap Opportunities Fund, Russell 2000 Index and S&P 500 performed in the pre and post bubble market of 1999. The results are very striking. Unfortunately, the Russell Microcap Index was not created until 2005, so hence, the reason that Index is not included. The bottom line to us is that small-cap cycles can be very powerful when they occur, and we hope to soon be partying like it’s 1999 again. We provided several other charts from our friends at Furey Research, which give us more confidence in the next positive small-cap cycle.

Click here for standardized performance.

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Performance data to the most recent month end may be obtained by calling (800) 331-8936. The fund imposes a 2% redemption fee on shares held for less than 90 days. Performance data does not reflect the redemption fee. If reflected, total returns would be reduced. The inception date for the Russell Microcap Index was 6/01/2005, therefore no average annual return figures for the 20-year period are available.

 

Manager Commentary, 2nd Quarter 2019

Whac-a-Mole

Lately it feels like the market has been playing a game of Whac-a-Mole. The moles (market worries) pop up from their holes at random and the market moves down accordingly until the mole goes back into its hole, or the worries have been placated. There are many types of “moles”: recession, longevity of this bull market, interest rates, Trump, Iran, tariffs, and rising levels of debt to name a few. We can see some mole events in the following chart as indicated by the red spikes and the market reaction to them.

The biggest threat may be the Fed and interest rates. In May, Powell said it was unlikely the Fed would cut rates. As soon as a month later, he indicated that the case for a rate cut was strengthening. The market and the Fed seem to be at odds though. Futures trading points to four cuts in the next year. We could see a big drop in the market if the Fed doesn’t acquiesce. The case for cutting rates does seem stronger though: global economic data is mixed, tax-cut stimulus is finished, and the trade war is taking a toll.

This has all resulted in many nervous investors. They have turned to bonds and other vehicles, such as low volatility ETFs and Quality ETFs to minimize a downfall in the market. Individual investors are on track to buy a majority of the U.S. government’s newly issued longer term debt. This is a first since the Treasury Department began publishing data from its auctions. The 10-year Treasury note has fallen to multi-year lows.  An investor recently stated, “What they’re yielding right now doesn’t matter – I’m looking for downside protection.”  Are we headed the way of Europe and Japan?  Negative interest rates in Europe and Japan have left investors effectively paying governments to hold their money when they purchase 10-year government securities. Funds that focus on low volatility have also become popular taking in nearly $12 billion year to date, more than double that of any other factor this year and the most for a six-month period since 2016.

 

IN THE NEWS…

Manager Commentary, 4th Quarter 2018

Flash Market Update

Investors did not take the news well from the Federal Reserve.  While most investors expected the Fed to raise interest rates by 25 basis points before year end, most were hoping further increases would be unlikely.  Instead, the Fed said two more increases in interest rates would be likely next year.  This news sent stocks to new lows for the year.

Despite one of the worst weekly and monthly declines in U.S. stocks and the increased nervousness by investors, there are several indicators that lead us to be more bullish on stocks.

For the past week, the S&P 500 Index lost 7.1%, the Russell 2000 Index lost 8.4%, and the Russell Microcap Index lost 9.0%.

If the December month were to end today, this would be the worst December in stock market history.  While large stocks are not officially in bear market territory yet, we might as well call it a bear market since nearly 50% of large stocks are down more than 20% from their highs.  Small stocks are officially in bear market territory with a decline of more than 25% for both the Russell 2000 and Russell Microcap Indexes. We also monitor the LD Microcap Index, which is down nearly 35% from its high and down more than 30% for the year.  While history has taught us that stocks can go lower in bear markets, this is also an excellent time for long-term investors to consider purchasing more equity holdings.

Unless a huge rally happens in the last week of the year, this will be the first year in more than 100 years that more than 90% of all asset classes finished down for the year.  This is also telling us it could be a great time for long-term investors.  I should caution investors, though, we believe the real leaders of the next bull market will likely be a different group of stocks than we saw in this past bull market.

• The put/call ratio for the market hit a record reading of 1.82, which is about the same level in the first week of March 2009, which was the bottom of the Great Recession.  While there is a great level of uncertainly in this market today, there is no structural economic issues like we had in 2008/2009 market.
• Let’s remember that 2017 was one of the least volatile years on record, as the S&P 500 was up each month and never fell more than 3% during the entire year.  We believe part of the relentless selling pressure may be related to tax-loss selling.  This is the first major decline in stocks in nearly 10 years, which means it could be the first year for investors to realize losses.  In addition, investment professionals have been trained to always mine losses for tax efficient reasons.  We think there is good chance for a strong bounce in stocks in the beginning of the year.
• According to American Association of Individual Investors (AAII), the bearish sentiment soared last week to nearly a 49% reading.  This contrarian indicator reading has not been that high since April 2013, which was a good entry point for stock investors.  It may be another great time for long-term investors today as well.
• According to Lipper Analytical, investors redeemed nearly $50 billion of domestic equity funds in the second week of December and purchased more than $80 billion of money market mutual funds.  This selling is a new record for weekly outflows, which we believe is another bullish contrarian indicator.

Despite all these contrarian positive indications, we believe the probability of a recession in the future has increased.  In our view,  the only lead indicator pointing to a recession is the stock market.  While it is unclear, we could be in a painful transition of stock market leadership, rather than recession.

Each of these indicators show that investors have become very fearful of the equity markets.  As Warren Buffet has said many times, “Be fearful when others are greedy, and be greedy when others are fearful.”¹  Given all these negative readings, it appears to be a great time for long-term investors to add to their equity holdings.  I, for one, will be adding to my equity holdings soon.

I hope everyone has a great holiday season.  If you have any questions about my comments, the markets, or the economy, please feel to email me at corbett@perrittcap.com or call 800-331-8936.

Michael Corbett
President
Perritt Capital Management

 

Manager Commentary, 3rd Quarter 2018

DON’T FIGHT THE FED

It is with great sadness that I inform everyone that our founder, Dr. Gerald W. Perritt, passed away this past month. Not only was Dr. Perritt my teacher and mentor, he was a dear friend.  Dr. Perritt taught me many things about life and certainly investments.  His first lesson and used often was to always investigate before you invest.  Given the current environment, I am often reminded of another one of Dr. Perritt’s lessons: Don’t Fight the Fed!  The Federal Reserve has three key objectives for monetary policy: maximizing employment, stabilizing prices and moderating long-term interest rates.  Regardless of what many observers may say, the Fed generally is not concerned about increased stock market volatility.  The Fed is more concerned about their mandate and the economy.  While it can be argued that inflation does appear to be a threat, there are also signs of only a modest uptick in inflation.  To us, the bottom line is the Fed is moving to get interest rates to a normal level, which is a perception problem.  Since interest rates have been exceptionally low for nearly 10 years, we believe many investors think we are already at a normal range for interest rates.  Again as Dr. Perritt always reminded me, it is always a great idea to use history as a guide. So, let’s review history for interest rates.  The tables below show the real history of the economy and interest rate policy.  You can draw your own conclusion, but we believe interest rates still need to be higher to reach a normal interest rate policy.

Fed Funds Rate History

This chart shows the fed funds rate changes since 1971.  Its complete history from 1954 to the present is found at the Federal Reserve Bank of St. Louis.

Dr. Gerald W. Perritt

“We are sad to report the loss of our founder, friend, teacher and mentor.  Dr. Perritt was a pioneer in the mutual fund industry.  He was one of the first in the industry to track performance and industry dynamics, and to champion mutual funds as an investment option.  He launched The Mutual Fund Letter in 1981, a monthly newsletter tracking the mutual fund industry.  Dr. Perritt’s flagship newsletter was Investment Horizons where he recommended micro-cap stocks.  He also created the Perritt MicroCap Opportunities Fund, one of the first micro-cap mutual funds, in 1988,” stated Michael Corbett, the current CEO of Perritt Capital Management.

Dr. Perritt was a prolific writer, sharing his insights and expertise through newsletters and several books, including Small Stocks, Big Profits, Mutual Funds Made Easy, and Expanding Your Investment Horizons. He was also a columnist for Forbes Magazine. Dr. Perritt was frequently quoted in such publications as The Wall Street Journal and Barron’s Magazine. He was always generous to share his wisdom, knowledge and experience with his staff, grooming successful investors.

Teaching was a passion for Dr. Perritt.  He taught and mentored many throughout his illustrious career.  He served as a professor at several prestigious universities, including Ball State University, Babson College, University of Miami and DePaul University.

Michael Corbett added, “our thoughts and prayers are with Dr. Perritt’s family and loved ones.”

Perritt Funds Tax Distribution Update

The Perritt MicroCap Opportunities Fund, the Perritt Ultra MicroCap Fund and the Perritt Low Priced Stock Fund will pay a long-term capital gains distribution on 11/14/18 to shareholders. Based on our estimates:

• The long-term capital gains distribution in the Perritt MicroCap Opportunities Fund (PRCGX) will be approximately 12%, roughly 6% in the Perritt Ultra MicroCap Fund (PREOX), and about 5% in the Perritt Low Priced Stock Fund (PLOWX).
• Any income or short-term gains in our Funds will be paid on 12/27/18 to shareholders of record on 12/26/18.

Long-Term Capital Gains distribution:

Distribution figures and distribution dates are estimates only and are subject to change. Actual distributions may be substantially different (higher or lower) or may not be distributed at all.

Actual distributions on a dollar per share basis will be available on or after 11/14/2018.

Any tax or legal information provided isn’t an exhaustive interpretation of some of the current income tax regulations or legal counsel for advice and information concerning their particular situation. Neither the Fund nor any of its representatives may give legal or tax advice.

Manager Commentary, 1st Quarter 2018

JEKYLL and HYDE QUARTER

The first quarter of 2018 was remarkable in several ways. We saw record highs in equity markets, but also a fierce resurgence in volatility. To some degree, the first quarter was a Jekyll and Hyde type of period. The first half of the quarter was characterized by a low volatility, momentum driven, continuation of the themes that carried 2017. While the second half of the quarter brought in a new regime, with explosive volatility, a refocusing of investors attention on fundamentals, and new leadership in the market. The rest of our commentary this quarter will help explain how the Perritt MicroCap Opportunities Fund (“the fund”) performed during these two distinct market environments, and the reasons behind that performance.

As an active manager, the fund has a less than 1.0 correlation to its benchmark as of 3/31/18. This is driven by distinct sector weight differences, weighting of individual stocks in the portfolio, and stylistic investment differences from the composition of the benchmark. The fund has regularly experienced significant positive and negative deltas in performance relative to the benchmark.

Below is a chart of the rolling delta of trailing 12-month performance between the fund and the Russell Microcap Index (“the benchmark”) as of 3/31/2018:

Click here for performance.

Performance data quoted represents past performance; past performance does not guarantee future results.  The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be lower or higher than the performance quoted.  Performance data current to the most recent month end may be obtained by calling 800-331-8936.

 

We find the 12-month rolling performance delta, from the 6/30/2000 inception through 3/31/2018, to be a highly mean reverting series. The average 12-month performance delta since the inception of the benchmark data (6/30/2000) is +2.3%, reflecting our long-term outperformance. The standard deviation is 7.2%, which indicates that there can be periods where we significantly outperform or underperform.

On a trailing 12-month basis, our performance relative to the benchmark Russell Microcap Index during the first quarter of 2018 reached -10.83%. This represented -1.8 standard deviations from our mean rolling 12-month performance since 2001. An extreme that lies in the bottom 98th percentile of relative 12-month returns. This was an outcome we were quite unpleased with, but one we understood to be an extreme, and yet, also not unprecedented. After being participants in the U.S. Microcap equity market for nearly 30 years, we understand cycles, even extremes ones, come and go. Historically however, +/- 1.5 standard deviations has been a reliable inflection point for mean reversion of our relative performance.

In the final analysis, we believe a confluence of market factors led to this recent period of underperformance, which hit a nadir in the middle of the first quarter of 2018. We trace the sources of this underperformance to the following factors: 1) disproportionate share of market gains being produced by narrow segments of the market, which we do not participate in, 2) outperformance of larger markets capitalization names within the index, vs. the sub-$500mm market capitalization segment we target, 3) stylistic headwinds, namely growth outperforming value, and 4) larger errors of commission than our historical average. It was our belief that many of these factors are reliably mean reverting. And thus, we expected performance to rebound from the February lows. Which it did in the second half of Q1, wonderfully.

We expect our performance to continue to positively and significantly mean revert. Despite the cyclically of underperformance and outperformance periods, the fund has outperformed its benchmark since inception.

Drivers of Recent Underperformance

1. Concentration of benchmark performance in Healthcare (Biotech/Pharma) and Technology (Internet Software/Software):

Below is the Russell Microcap Index attribution from 3/7/2017-3/7/2018. This period captures the trailing 12-month period ending at the low point of our recent underperformance cycle.

The Russell Microcap Index gained 18.91% from 3/7/2017-3/7/2018. However, the majority of sectors “underperformed.” Two sectors alone drove 60% of the index performance. Healthcare, which gained +38.35%, added +803bps to the return and technology, which gained +23.70%, added +327 bps to the return.

The Telecomm sector performance was primarily driven by a single company being acquired (STRP), and the sector’s low weighting (1.0%) causes the contribution to be relatively immaterial. The Healthcare (index weight of 21.9%) and Technology (index weight of 13.4%.) sectors were the strongest contributors within the Russell Microcap Index.

Roughly 40% of the index performance has been concentrated in the subsectors of Biotechnology, Pharmaceutical and Software. As a value-oriented manager who strives to build a portfolio of securities issued by companies with sustainable, profitable business, we find ourselves unable to generate many investable ideas in these subsectors. During the prior year, the fund maintained a 0% exposure to the Biotech/Pharma sectors, and a 2.8% exposure in Software, all significantly below the benchmark weights.

Of the top twenty-five performing stocks in the index, fifteen are Biotech/Pharma related. Of those same twenty-five, only four are profitable companies, and nine have $10mm or less in revenues.

The top 25 performing stocks show an unusual degree of extreme price performance with an average gain of 359%, as well as narrow industry concentration.

2. Performance By Market Capitalization segment 3/7/2017-3/7/2018:

Stocks with larger beginning market capitalizations significantly outperformed stocks of smaller sized companies. The fund targets companies with market capitalizations of less than $500mm, and has a median market cap of $309mm.

3. Growth vs. Value

Growth has significantly outperformed value in the previous 14 months. We find growth vs. value relative performance to be highly mean reverting. The level of growth outperformance reached in Q1 2018 has previously been an inflection point a number of times over the past 10 years.

We also measure growth vs. value by the performance of securities grouped by valuation:

Higher multiple stocks have significantly outperformed stocks trading at lower valuations. The fund median revenue multiple is currently approximately 1.0x, less than half the Russell Microcap Index median revenue multiple of 2.1x.

As a value focused manager, we have historically managed the fund with a significantly lower level of valuation than the broader markets and benchmark. We find broader market valuations to currently be well above average. In our opinion, the securities we have in the portfolio provide a better long-term risk/reward opportunity.

4. Errors of Commission

The fund’s top and bottom performers as measured by contribution to the fund’s performance:

As our mission has always been, the fund has continued to capitalize on unique opportunities we find in the microcap asset class. Our top five performing positions contributed +635bps to our return. However, our bottom five performing positions detracted -423bps. While it is of significant importance in our minds to have your winners contribute more than the losers detract, the spread of winners-losers was less than we target. Historically, we have a positive spread in our top five vs. bottom five. In the preceding 5 years (2011-2016), we had a ratio of top five contribution to bottom five detraction of roughly 3:1. In the recent period this ratio is 1.5:1. The narrower spread has been driven by larger than historical detractions by individual positions.

Mean Reversion and the Performance Turnaround

As we’ve now stated many times in this commentary, we firmly believed our performance had potential to recover based on the historical evidence that many of the drivers of our underperformance we’re reliably mean reverting. From 3/7/2018 through the end of the quarter, the Perritt MicroCap Opportunities Fund gained +2.97%, while the benchmark declined -2.86%, for a performance delta of +583bps in three and a half weeks! This cut our rolling 12 month performance delta to the benchmark down to -3.06%.

While we believe that the securities purchased for the fund’s portfolio trade at significant discounts to intrinsic value, the timing of the realization is often highly uncertain. In many cases, securities can trade at a significant discount for years. This can weigh on fund performance in the short term, as we hold these securities awaiting closure of the intrinsic value to market value gap. In our experience, the gap to intrinsic value, which may have been stubbornly persistent for years, can dramatically narrow in very short periods of time. As examples, we saw this dynamic in late Q1 in our top two holdings, BXC and ADUS.

BlueLinx Holdings Inc. (BXC), our top holding, is a stock that had underperformed the market for years. The company recently announced two major catalytic events, a real estate divestiture and an acquisition, which we had anticipated, and the stock moved from the $15 range to $32 to close the quarter (and now $41 as of 4/23/2018). This is a 100%+ gain in a 3 week period from a stock which had “gone nowhere” for years.

Addus Homecare Corp. (ADUS), our second largest holding, presents a similar, though admittedly, less extreme case. Nevertheless, ADUS highlights how quickly the performance contribution from a single position can change from being a detractor to a contributor. We have held ADUS for many years and have a cost basis of less than $7 per share. The stock closed the quarter at $48 (and is $54 as of 4/23/2018). Though a significant contributor to long-term performance, it is not a consistent contributor to performance. As an example, the stock closed 2017 down -1%, vs. a gain for the Russell Microcap index of +13%. ADUS was a significant drag on the Fund’s performance for the calendar year 2017, despite being a hugely successful long term holding. After announcing an acquisition in Q1 2018, the stock moved from ~$34 to $48 to close the quarter. The stock is now again outperforming the market, and a positive contributor to relative performance.

The combination of reliably mean reverting factors reversing from a headwind to a tailwind, discussed at length in this commentary, and the opportunity to generate significant individual security alpha, gives our team confidence in our ability to seek to continue our long-term outperformance going forward.

Manager Commentary, 4th Quarter 2017

YEAR IN REVIEW

Worry?

There is an old saying on Wall Street that the markets climb a “Wall of Worry.” The past quarter and year certainly had several concerns, but the markets continued higher and finished the year at all time highs. Some of these recent concerns were several Hurricanes. Hurricane Harvey came first, pummeling Houston on August 25th. Less than two weeks later, Irma battered the Caribbean and Florida. Jose and Maria followed shortly after, striking the Caribbean and crushing Puerto Rico’s infrastructure. The cost is estimated to be in the hundreds of billions of dollars and will take years to repair. The financial markets hardly noticed.

Hurricanes were not the only concern. There were political debates over health care, the debt ceiling, the National Football League and the Russian investigation. Then there were words raged between North Korea’s supreme leader Kim Jong Un and President Donald Trump. The belated announcement of a data breach at Equifax, potentially impacting nearly one in every two Americans, increased the already big concern about cybersecurity. How about all the Trump Twitter Tweets? It goes on and on. I think you get my point. The bottom line is that it seems that nothing will bring this market down, and it continues to climb that “Wall of Worry.”

Market Results

For the fourth quarter of 2017, large stocks continued to be the leader. The S&P 500 Index climbed more than 6% in the fourth quarter and rose by more than 20% for 2017. Smaller stocks performed well, but lagged their large cap brethren. The table above shows the performance results for the small/micro-cap indexes from Frank Russell & Company. During the past year, growth trumped value in both small-cap and micro-cap indexes. However, value outperformed growth within the micro-cap indexes in the fourth quarter. We are not sure if value’s leadership within micro-cap stocks is in a leadership reversal.

A deeper drive into the small/micro-cap universe shows that while the breadth was strong, it was not as strong as one might think given the gains last year. The table below shows the number of stocks that posted gains versus the number of stocks posting losses last year. Of the 3,244 publicly traded small/micro-cap stocks, 1,878 rose last year while 1,366 declined last year. A more interesting data point is that while the standard stock climbed nearly 15% last year, the median gain was only 5.51%. To us, the true standard company’s stock did not perform well last year. We believe there is a decent chance that the standard stock may do better in the future. Let’s look at several factors that could influence small/micro-cap stocks in 2018.

Interest Rates

Including yours truly, there have been many professional investors that have been forecasting higher interest rates for many years. The Federal Reserve spent the past year beginning the process of resetting short-term interest rates. Bond vigilantes may follow this year and reset yields. However, there have been several times in this recovery when bond yields attempted to rise only to be terminated and reversed. The obvious reason for this is that the U.S. economic data turned soft, but we think most of the blame came from other markets, which included Eurozone blowing up, China economy slowing, or various other global economic issues. This period, however, the U.S. recovery is broader, global recovery is more synchronized, confidence is stronger among businesses and individuals, and we are closer to full employment than ever.

The 10-year Treasury yield is currently just above 2.60%, which is up from 2.12% from July 2017 and 1.46% in June 2016. While inflation is still relatively low, it appears inflation is rising, and more importantly, inflation expectations appear to be on the rise. Should evidence support an increase in inflation, it should force yields to head even higher. Bonds have been in a bull market for more than 30 years, but given the current economic backdrop we believe the bond bull market is over. Even the charts support this theory. If you examine the long-term trend line of all the government bond yields, you will see most government bonds have broken their long-term trend line. The 30-year Treasury Bond is the only bond that has not broken the long-term trend line. We believe once the 30-year Treasury Bond breaks its long-term trend line, the bond market will officially enter a bear market. We have often said that rising interest rates are not a bad thing for smaller stocks. Smaller stocks have performed well in rising interest environments. Please refer to our white paper on Interest Rate Hikes and Small Cap Returns.

Tax Cut

The Trump Administration was successful in lower taxes for corporations. It depends on your individual situation, but taxes were lowered for some individuals too. The corporate tax rate was permanently lowered from 35 percent to 21 percent, which brings the rate closer to countries like Canada at 15 percent and Ireland at 12.5 percent. Analysts are busy reviewing financials to adjust their earnings estimates for 2018 and 2019. Since several companies have operations around the world and some have tax deferred assets that need to be adjusted or written down, the adjustment to earnings estimates is not that easy. We, and many analysts have a great deal of homework. Earnings estimates need to be adjusted for these new facts. Regardless, estimates for the several companies will be on the rise, which we believe should be a net positive for stock prices. In addition, we believe higher corporate profits and increased cash flow should bode well for merger and acquisition activity. As you may have seen from our research, as of 12/31/17 nearly 60% of all public merger and acquisition activity occurs at the micro-cap level. Please refer to our white paper on Top 10 Reasons to Invest in Microcap.

U.S. Economy and Global Growth

The U.S. economy experienced two quarters in a row of economic growth above 3%, and unemployment is near a 50-year low. The Trump Administration continues to lobby for its pro-growth agenda. The pro-growth agenda includes slashing onerous regulations that have stifled business, a proposed $1 trillion infrastructure spending schedule for this year, a signifi- cant increase in military budget, and the already passed tax cuts discussed above.

Global growth is improving overseas too. We are in the middle of a global economic growth recovery which has provided strong support for market gains. For the first time since 2007, all 45 economies tracked by the OECD (Organization for Economic Co-operation and Development) Composite Leading Indicators Index have positive GDP growth for the year. Furthermore, despite minor interest rate increases in the U.S., global central bank policies remain very accommodating with low interest rates around the world. Most importantly, recession risk in the next year could be low.

There are few excesses you would normally associate with a recovery like this one. Both household and businesses have strong and liquid balance sheets, and will likely improve with the recent tax cuts. The Leading Economic Indicators (LEI) just rose to a new all time high. In our view, the U.S. has not experienced a meaningful capital spending cycle since the Dot-com boom in the 1990s, but we believe the conditions are more conducive for investments. We would not be surprised if the U.S. economy produces growth near 4% or more in one of the quarters this year.

Valuations and Investment Outlook

Given the fact that stock prices rose by double digits in each of the past two years, and corporate profits rose, but by less than stock prices during that period, one should be concerned about valuations. We certainly agree that valuations are not cheap. Just review the table below. This is the small-cap universe of 3,244 companies broken down for various market capitalization ranges. The typical company within the small-cap universe trades at more than 22 times trailing earnings, which is not cheap in our opinion. However, with the economy still improving and corporate tax cuts now in place, earnings growth should be very robust this year, which means valuations may be lower in the future.

Given our thoughts on interest rates, tax cuts, and the global economy, our investment focus remains on capital good sectors. Throughout most of the bull market, leadership has been concentrated among consumer stocks and bond surrogates. However, investment spending seems to be in a position to drive the capital goods area. We view the four major capital good sectors as technology, industrial, materials, and energy. We believe technology represents the leaders and are characterized by string secular unit growth. Industrials offer a play on global infrastructure revival. Materials are the quintessential inflations play in the economy, and are likely to face intensifying overheat pressures. Lastly, Energy offers a contrarian play, but good value which could benefit from rising inflation and higher yields. While we will not entirely ignore the other sectors of the economy, it is likely that these capital good sectors will be our larger weights within the portfolios.